Memantine restores long term potentiation impaired by tonic N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg2+ In hippocampal slices

Neuropharmacology

Volumn 38, Issue 9, 1999, Pages 1253-1259

  Frankiewicz, Tadeusz ^a   Parsons, Chris G ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

(+)MK 801; Hippocampal slice; Long term potentiation; Memantine; Mg2+; N Methyl D aspartate receptor; Tonic activity

Indexed keywords

DIZOCILPINE; MAGNESIUM; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DOSE RESPONSE; HIPPOCAMPUS; IN VITRO STUDY; LONG TERM POTENTIATION; MALE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; HIPPOCAMPUS; MAGNESIUM; MALE; MEMANTINE; OXIDATION-REDUCTION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0032810628     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(99)00060-X     Document Type: Article

References (36)

1. Anderson W.W., Collingridge G.L. A data acquisition program for on-line analysis of long-term potentiation. Soc. Neurosci. Abs. 23:1997;264.19.
2. Barnes C.A., Danysz W., Parsons C.G. Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur. J. Neurosci. 8:1996;565-571.
3. Benveniste M., Mienville J.M, Sernagor E., Mayer M.L. Concentration-jump experiments with NMDA antagonists in mouse cultured hippocampal neurons. J. Neurophysiol. 63:1990;1373-1384.
4. Benveniste M., Mayer M.L. Kinetic analysis of antagonist action at N-methyl-D-aspartic acid receptors. Two binding sites each for glutamate and glycine. Biophys. J. 59:1991;560-573.
5. Blanpied T.A., Boeckman F.A., Aizenman E., Johnson J.W. Trapping channel block of NMDA-activated responses by amantadine and memantine. J. Neurophysiol. 77:1997;309-323.
6. Bliss T.V.P., Collingridge G.L. A synaptic model of memory-long-term potentiation in the hippocampus. Nature. 361:1993;31-39.
7. Chen H.S.V., Pellegrini J.W., Aggarwal S.K. et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine-therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 12:1992;4427-4436.
8. Clements J.D., Lester R.A.J., Tong G., Jahr C.E., Westbrook G.L. The time course of glutamate in the synaptic cleft. Science. 258:1992;1498-1501.
9. Coan E.J., Irving A.J., Collingridge G.L. Low-frequency activation of the NMDA receptor system can prevent the induction of LTP. Neurosci. Lett. 105:1989;205-210.
10. Collingridge G.L., Bliss T.V.P. Memories of NMDA receptors and LTP. Trends Neurosci. 18:1995;54-56.
11. Danysz W., Parsons C.G., Bresink I., Quack G. Glutamate in CNS disorders. Drug News Perspect. 8:1995;261-277.
12. Danysz W., Zajaczkowski W., Parsons C.G. Modulation of learning processes by ionotropic glutamate receptor ligands. Behav. Pharmacol. 6:1995;455-474.
13. Danysz W., Parsons C.G., Kornhuber J., Schmidt W., Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies. Neurosci. Biobehav. Rev. 21:1997;455-468.
14. Dhooge R., Raes A., Vanbogaert P.P., Geelhand M., Dedeyn Selective block of N-methyl-D-aspartic acid (NMDA)-evoked whole-cell currents in mouse cultured spinal neurones by CGP 40116. Br. J. Pharmacol. 120:1997;211-214.
15. Ditzler K. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Arzneim. Forsch. Drug Res. 41:1991;773-780.
16. Ferkany J.W., Hamilton G.S., Patch R.J. et al. Pharmacological profile of NPC 17742 [2R,4R,5S-(2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid)], a potent, selective and competitive N-methyl-D-aspartate receptor antagonist. J. Pharmacol. Exp. Ther. 264:1993;256-264.
17. Frankiewicz T., Potier B., Bashir Z.I., Collingridge G.L., Parsons C.G. Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br. J. Pharmacol. 117:1996;689-697.
18. Frankiewicz, T., Pilc, A., Parsons, C.G., 1999. Differential effects of NMDA-receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices. Neuropharmacology, (submitted).
19. Hess S.D., Daggett L.P., Crona J. et al. Cloning and functional characterization of human heteromeric N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. 278:1996;808-816.
20. Kawajiri S., Dingledine R. Multiple structural determinants of voltage-dependent magnesium block in recombinant NMDA receptors. Neuropharmacology. 32:1993;1203-1211.
21. 3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur. J. Pharmacol. 166:1989;589-590.
22. Misztal M., Frankiewicz T., Parsons C.G., Danysz W. Learning deficits induced by chronic intraventricular infusion of quinolinic acid - protection by MK-801 and memantine. Eur. J. Pharmacol. 296:1996;1-8.
23. Misztal M., Danysz W. Comparison of glutamate antagonists in continuous multiple-trial and single-trial dark avoidance. Behav. Pharmacol. 6:1995;550-561.
24. Mondadori C., Weiskrantz L., Buerki H., Petschke F., Fagg G.E. NMDA receptor antagonists can enhance or impair learning performance in animals. Exp. Brain Res. 75:1989;449-456.
25. Morris R.G.M. Preconceptions and prerequisites: understanding the function of synaptic plasticity will also depend on a better systems - level understanding of the multiple types of memory. Beh. Brain Sci. 20:1997;624.
26. Müller W.E., Mutschler E., Riederer P. Noncompetitive NMDA receptor antagonists with fast open- channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Pharmacopsychiatry. 28:1995;113-124.
27. Parsons C.G., Gruner R., Rozental J., Millar J., Lodge D. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology. 32:1993;1337-1350.
28. Parsons C.G., Quack G., Bresink I. et al. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology. 34:1995;1239-1258.
29. Parsons C.G., Danysz W., Quack G. Glutamate in CNS Disorders as a target for drug development: an update. Drug News Perspect. 11:1998;523-569.
30. Parsons C.G., Danysz W., Quack G. Memantine is a clinically well tolerated NMDA receptor antagonist-a review of preclinical data. Neuropharmacology. 38:1999;735-767.
31. Rogawski M.A. Therapeutic potential of excitatory amino acid antagonists - channel blockers and 2,3-benzodiazepines. Trends Pharmacol. Sci. 14:1993;325-331.
32. Schulz J.B., Matthews R.T., Henshaw D.R., Beal M.F. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience. 71:1996;1043-1048.
33. Varney M.A., Jachec C., Deal C. et al. Stable expression and characterization of recombinant human heteromeric N-methyl-D-aspartate receptor subtypes NMDAR1A/2A and NMDAR1A/2B in mammalian cells. J. Pharmacol. Exp. Ther. 279:1996;367-378.
34. Wenk G.L., Danysz W., Mobley S.L. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur. J. Pharmacol. Environ. Toxicol. 293:1995;267-270.
35. Zajaczkowski W., Quack G., Danysz W. Infusion of (+)-MK-801 and memantine - contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur. J. Pharmacol. 296:1996;239-246.
36. Zajaczkowski W., Frankiewicz T., Parsons C.G., Danysz W. Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology. 36:1997;961-971.